Erratum

Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes (Diabetes Care (2009) 32 (2300-2306) DOI: 10.2337/dc09-1297)

Andrew D. Calvin, Niti R. Aggarwal, Mohammad H Murad, Qian D Shi, Mohamed B. Elamin, Jeffrey B. Geske, M. Merce Fernandez-Balsells, Felipe N. Albuquerque, Julianna F. Lampropulos, Patricia J. Erwin, Steven A. Smith, Victor Manuel Montori

Research output: Contribution to journalComment/debate

Abstract

In the article cited above, Fig. 2 should have shown the pooled relative risks and 95%CI for the effect of aspirin versus control on death, myocardial infarction, and ischemic stroke, respectively, stratified by diabetes status of the trial participants. The published version of the manuscript incorrectly labeled the plots. In verifying every data point on the figure, the authors found discrepancies on the values reported for the Early Treatment Diabetic Retinopathy Study (ETDRS), particularly in the denominators used, which should have reported 1,856 patients with diabetes allocated to aspirin and 1,855 participants without diabetes allocated to placebo. The authors are grateful to the colleagues who noted this discrepancy and brought it to their attention and for the opportunity, almost a decade later, to correct the published record. The corrected Fig. 2 (3 panels) and the corrected legend are published below. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)1321-1322
Number of pages2
JournalDiabetes Care
Volume41
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Primary Prevention
Aspirin
Meta-Analysis
Manuscripts
Diabetic Retinopathy
Stroke
Myocardial Infarction
Placebos
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Erratum : Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes (Diabetes Care (2009) 32 (2300-2306) DOI: 10.2337/dc09-1297). / Calvin, Andrew D.; Aggarwal, Niti R.; Murad, Mohammad H; Shi, Qian D; Elamin, Mohamed B.; Geske, Jeffrey B.; Fernandez-Balsells, M. Merce; Albuquerque, Felipe N.; Lampropulos, Julianna F.; Erwin, Patricia J.; Smith, Steven A.; Montori, Victor Manuel.

In: Diabetes Care, Vol. 41, No. 6, 01.06.2018, p. 1321-1322.

Research output: Contribution to journalComment/debate

Calvin, Andrew D. ; Aggarwal, Niti R. ; Murad, Mohammad H ; Shi, Qian D ; Elamin, Mohamed B. ; Geske, Jeffrey B. ; Fernandez-Balsells, M. Merce ; Albuquerque, Felipe N. ; Lampropulos, Julianna F. ; Erwin, Patricia J. ; Smith, Steven A. ; Montori, Victor Manuel. / Erratum : Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes (Diabetes Care (2009) 32 (2300-2306) DOI: 10.2337/dc09-1297). In: Diabetes Care. 2018 ; Vol. 41, No. 6. pp. 1321-1322.
@article{f29f86d6be8e47b2818267a58c3e7489,
title = "Erratum: Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes (Diabetes Care (2009) 32 (2300-2306) DOI: 10.2337/dc09-1297)",
abstract = "In the article cited above, Fig. 2 should have shown the pooled relative risks and 95{\%}CI for the effect of aspirin versus control on death, myocardial infarction, and ischemic stroke, respectively, stratified by diabetes status of the trial participants. The published version of the manuscript incorrectly labeled the plots. In verifying every data point on the figure, the authors found discrepancies on the values reported for the Early Treatment Diabetic Retinopathy Study (ETDRS), particularly in the denominators used, which should have reported 1,856 patients with diabetes allocated to aspirin and 1,855 participants without diabetes allocated to placebo. The authors are grateful to the colleagues who noted this discrepancy and brought it to their attention and for the opportunity, almost a decade later, to correct the published record. The corrected Fig. 2 (3 panels) and the corrected legend are published below. (Figure Presented).",
author = "Calvin, {Andrew D.} and Aggarwal, {Niti R.} and Murad, {Mohammad H} and Shi, {Qian D} and Elamin, {Mohamed B.} and Geske, {Jeffrey B.} and Fernandez-Balsells, {M. Merce} and Albuquerque, {Felipe N.} and Lampropulos, {Julianna F.} and Erwin, {Patricia J.} and Smith, {Steven A.} and Montori, {Victor Manuel}",
year = "2018",
month = "6",
day = "1",
doi = "10.2337/dc18-er06a",
language = "English (US)",
volume = "41",
pages = "1321--1322",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Erratum

T2 - Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes (Diabetes Care (2009) 32 (2300-2306) DOI: 10.2337/dc09-1297)

AU - Calvin, Andrew D.

AU - Aggarwal, Niti R.

AU - Murad, Mohammad H

AU - Shi, Qian D

AU - Elamin, Mohamed B.

AU - Geske, Jeffrey B.

AU - Fernandez-Balsells, M. Merce

AU - Albuquerque, Felipe N.

AU - Lampropulos, Julianna F.

AU - Erwin, Patricia J.

AU - Smith, Steven A.

AU - Montori, Victor Manuel

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In the article cited above, Fig. 2 should have shown the pooled relative risks and 95%CI for the effect of aspirin versus control on death, myocardial infarction, and ischemic stroke, respectively, stratified by diabetes status of the trial participants. The published version of the manuscript incorrectly labeled the plots. In verifying every data point on the figure, the authors found discrepancies on the values reported for the Early Treatment Diabetic Retinopathy Study (ETDRS), particularly in the denominators used, which should have reported 1,856 patients with diabetes allocated to aspirin and 1,855 participants without diabetes allocated to placebo. The authors are grateful to the colleagues who noted this discrepancy and brought it to their attention and for the opportunity, almost a decade later, to correct the published record. The corrected Fig. 2 (3 panels) and the corrected legend are published below. (Figure Presented).

AB - In the article cited above, Fig. 2 should have shown the pooled relative risks and 95%CI for the effect of aspirin versus control on death, myocardial infarction, and ischemic stroke, respectively, stratified by diabetes status of the trial participants. The published version of the manuscript incorrectly labeled the plots. In verifying every data point on the figure, the authors found discrepancies on the values reported for the Early Treatment Diabetic Retinopathy Study (ETDRS), particularly in the denominators used, which should have reported 1,856 patients with diabetes allocated to aspirin and 1,855 participants without diabetes allocated to placebo. The authors are grateful to the colleagues who noted this discrepancy and brought it to their attention and for the opportunity, almost a decade later, to correct the published record. The corrected Fig. 2 (3 panels) and the corrected legend are published below. (Figure Presented).

UR - http://www.scopus.com/inward/record.url?scp=85047469139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047469139&partnerID=8YFLogxK

U2 - 10.2337/dc18-er06a

DO - 10.2337/dc18-er06a

M3 - Comment/debate

VL - 41

SP - 1321

EP - 1322

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -